Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06711731

The Freiburg Registry on SpontanEous IntercrAnial Hypotension (SIH) & Post-duraL Puncture Headache (PDPH)

Spinal CSF leaks are considered as rare disease. They cause a variety of symptoms, mainly culminating in a chronic headache syndrome. Crucially, yet often disregarded, the disease holds the potential for cure. The multitude of symptoms, and their inconsistency over time are just two of many challenges preventing timely diagnosis and treatment in many patients.

Spinal CSF leaks can occur after intentional or accidental dural puncture (post-dural puncture headache - PDPH) or spontaneously (spontaneous intracranial hypotension - SIH). Awareness is steadily increasing with simultaneous increase of recognized patients. Yet, research and diagnostic is mainly provided by few specialized centers, as e.g. Freiburg. Thus, many observations point towards a large non-diagnosed and non-recognized number of patients, most likely being misdiagnosed and mistreated.

Objective: The aim of the registry is to collect structured information on the frequency, cause, symptoms, diagnostic procedures, treatment options and long-term outcome. With the help of the registry, we would like to contribute to a better understanding and treatment of the diseases.

Methods: Prospective, longitudinal registry on patients with suspected SIH or PDPH, including data on demographics, clinical presentation, diagnostic findings, treatment, at treatment outcome.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Spinal CSF leaks have a severe impact on quality of life and health. Symptoms vary from chronic headache syndrome to intracranial bleeding, cognitive decline, and coma. Crucially, yet often disregarded, the disease holds the potential for cure.

Lumbar dural leaks can arise from commonly performed medical interventions such as diagnostic lumbar punctures, spinal anesthesia, spinal infiltrations, or incidental dural punctures during epidural analgesia in obstetric care, resulting in post-dural puncture headache (PDPH).

Additionally, a notable fraction of spinal CSF leaks manifests as spontaneous intracranial hypotension (SIH), which derives from different types of spontaneous leaks along the Spine and remains broadly under-recognized.

The main clinical symptoms of spinal CSF leaks are orthostatic headaches with a most often defined beginning, typically accompanied by hearing impairment and dizziness, worsened by exercise and movement. Additionally, other manifestations are known, such as cognitive decline, bilateral brachial amyotrophy, paradox headache, fatigue, and many more. In patients presenting with spinal CSF leaks, the accurate diagnosis often eludes clinicians, leading to frequent misdiagnoses of chronic migraine, fatigue, or psychiatric conditions. Many patients endure months, if not years, before a diagnosis of a treatable condition is finally established. The heterogeneity of the symptoms can appear inconsistent or even paradoxical, posing diagnostic challenges. The extent of possible long-term deterioration is not recognized.

The reported incidence of PDPH fluctuates considerably, ranging from 2 to 40 per 100 procedures performed. This variance is influenced by patient-related factors (e.g., age, gender, pregnancy status) and procedural factors (e.g., needle size and type). PDPH, according to current criteria, occurs within 5 days after a dural puncture. Nevertheless, there are widely underestimated pitfalls: a dural puncture is not always recognized by the person performing an epidural procedure, symptoms can occur after more than 5 days, and disease courses can be chronic. These facts are widely unknown, leading to largely hidden figures of patients being under or misdiagnosed and, thus, not treated. Moreover, PDPH is primarily observed following unintentional dural puncture during the administration of obstetric anaesthesia and analgesia to parturients.

Spontaneous intracranial hypotension (SIH) can be caused by ventral, lateral, or sacral spinal leaks or by CSF-venous fistulae, which was first described in 2014. An annual incidence rate of ~ 4/100,000 was estimated in 2022. This rate is likely underestimated as it only includes confirmed cases, thus recognized cases within a widely non-recognized entity. Often, patients are neither identified nor directed to the appropriate MRI, which, in numerous instances, could lead to the correct diagnosis. Even when SIH is identified, non-targeted epidural blood patches in the lumbar region are often not administered due to perceived elevated risks. An epidural blood patch might be able to help to heal the leak. At the same time, it must be noted that even long-term improvement does not necessarily indicate closure of the leak and prevention of long-term sequelae, such as superficial siderosis. Invasive diagnostics are not employed to pinpoint the location, and treatment to seal the leak is not consistently pursued. The effects of treatment are often immediate and can be successful even in chronic patients. Evidence shows that leaks are held open by new membranes (Neo-membranes) that prevent spontaneous healing. Thus, the correct localization of such a leak and targeted sealing or close follow-ups should be initiated.

The management approaches for SIH and PDPH significantly deviate from standard pain management strategies employed for other types of headaches. Noteworthy interventions include the application of blood patches and even surgical measures to seal the leak, offering curative solutions. Those enduring chronic spinal CSF leaks experience profound limitations in their health-related quality of life, comparable to those with chronic immunological diseases or cancer. Overlooking the diagnosis and management of spinal CSF leaks may precipitate progressive deterioration, with the potential for persistent sequelae like superficial siderosis, syndromes mimicking frontotemporal dementia (FTD), and chronic subdural hematoma formation.

This registry aims to set ground for standardized, prospective demographic, diagnostic and treatment data assessments, and patient self-reported outcome measures.

Collecting this data is essential to potentially exploring risk factors, understanding outcome predictors, and refining diagnostics. Additionally, standardized data collection will allow the appropriate designing of urgently needed randomized trials.

Aims:

Primary aim:

To describe the proportion of patients diagnosed with SIH or PDPH

Secondary aims:

  • To describe the proportion of different spinal CSF leaks observed per entity
  • To describe the demographics per entity, and per different spinal CSF leak type
  • To describe the clinical spectrum per entity, and per different spinal CSF leak type
  • To describe the imaging features per entity, and per different spinal CSF leak type
  • To describe the outcome of different treatments, and per different spinal CSF leak type
  • To describe the adverse events of different treatments, and per different spinal CSF leak type
  • To explore potential diagnostic markers per entity, and per different spinal CSF leak type
  • To explore risk factors per entity, and per different spinal CSF leak type
  • To evaluate differences between spinal CSF leak types regarding age, sex, BMI, clinical presentation, diagnostic findings
  • To assess the effect of disease duration on imaging findings, and on outcome after persistent closure of a leak

Method:

The registry is prospective, longitudinal and currently monocentric*. Diagnostic, treatment, and follow-up procedures follow clinical standard operating procedures (SOP) according to the suspected diagnosis and the clinical findings.

Routinely assessed data of the initial diagnostic workup and the individual's disease course with or without treatment will be collected over 2 years per individual. The investigators' semi-annual meetings ensure the achievement of the register's predefined aims.

There are no specific risks or benefits for the patients participating in this registry. Any procedure will be performed according to clinical standards as indicated. There will be no additional visits to the hospital or the ambulatory. There will be no additional imaging performed, especially no additional radiation.

A merely intrinsic benefit might exist for the patient supporting this study and supporting medical research.

As this is an explorative and observational study on rare diseases without formal sample size estimation, we limit the study by time of duration (10 years).

Patients suffering from rare diseases most often face delays in diagnostics and treatments. To underscore this known burden: By an estimated population of 1.74 Mio in the Freiburg area and an incidence rate of SIH of about 5/100.0004, approximately 85 patients should be expected per year stemming from this area. Freiburg is the only center offering adequate diagnostic pipelines for these patients. Despite the increasing awareness, the number of patients diagnosed in the area adjunct to the Freiburg CSF center is within a range of 15 to 20 patients per year, thus still too low compared to the expected number with many patients unrecognized, and or underdiagnosed.

Our current numbers of confirmed SIH treatments range from 100 per year with patients being referred throughout Germany and about 15-20 international patients per year. We expect this rate to rise within the next few years. The number of PDPH patients with a focus on persistent PDPH patients is currently rapidly increasing. We see about 40-60 per year.

Interim-Evaluation of the Registry's primary and secondary descriptive aims will be performed and reported as a step-wise, dynamic approach:

  • After each +100 patients with confirmed SIH
  • After each +50 patients with confirmed PDPH

The secondary objectives, which involve comparisons, the exploration of diagnostic markers, and risk factors, will be addressed using a dynamic biostatistical model: The analysis will only be conducted after a power analysis deems the observed sample adequate.

Proportions will be presented as a percentage with 95% confidence interval (CI).

The sata of patients with different types of spinal CSF leaks will be summarized using descriptive statistics, i.e. median and quartiles for continuous and absolute and relative frequencies for categorical variables, regarding their clinical, laboratory, and diagnostic findings, and number of diagnostic and therapeutic procedures needed.

Furthermore, the proportion of SIH patients with different spinal CSF leak types

  • will be compared between males and females using a Chi2-Test and a risk difference with 95% CI.
  • Will be presented by age groups (per two decades), and per sex as a percentage with a 95% Wilson confidence interval (CI).

Age, sex, BMI, clinical presentation, and diagnostic findings between different spinal CSF leaks will be compared using the Mann-Whitney-Wilcoxon test and Chi2 test for continuous and categorical variables, respectively.

A multivariable logistic regression for the presence of SIH, PDPH, and chronic PDPH, respectively, will be constructed using the clinical and diagnostic parameters with some evidence for a difference according to the presence of a spinal CSF leak (p < 0.2). The potential nonlinearity of the age effect is evaluated based on a residual analysis of the regression model. Odds ratios with 95% CI will be reported. Using bootstrapping, we will present a ROC curve and AUC with 95% Due to the exploratory approach,, no correction for multiple testing will be performed.

A multivariable linear regression for imaging findings (especially Bern Score, presence of SLEC, vand olumetries), and for the patient-reported outcomes will be constructed using the clinical and diagnostic parameters at admission with some evidence for a difference (p<0.2). Adjusted R-squares, Beta-coefficients with 95% CI, standard errors will be reported.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with suspected spinal CSF leak based on one of the following
  • History of new orthostatic symptomes with or without prior spinal procedure
  • Imaging suggestive for spinal CSF leak
  • Informed consent

Exclusion criteria

a) Symptoms beeing conclusively explained by another known diagnosis

Treatment and study plan

Primary outcomes

  1. Primary Diagnosis given after primary workup (yes/no)

    Time frame: up to 4 weeks after inclusion

    • SIH (fulfilling ICHD-3 criteria) - yes/no
    • atypical SIH - yes/on
    • Asymptomatic SIH (positive imaging signs only) - yes/no
    • PDPH (fulfilling ICHD-3-criteria) - yes/no
    • persistentPDPH - yes/no

Secondary outcomes

  1. SIH/PDPH - Experience of the local team

    Time frame: at time of inclusion

    Number of patient with suspicion for SIH work-up/year

  2. SIH/PDPH - Patients' demographics

    Time frame: at time of inclusion

    Country, City

  3. SIH - Previously received treatment at time of inclusion (yes/no)

    Time frame: at time of inclusion

    Medical SIH treatment, Other symptomatic treatment, Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery, Open surgery - dorsal approach, Open surgery-ventral approach, Open surgery-transforaminal approach, Discectomy, Laminectomy, Stabilization procedures, Surgery, other techniques

  4. SIH/PDPH - age

    Time frame: at time of inclusion

    years

  5. SIH/PDPH - sex

    Time frame: at time of inclusion

    male female diverse

  6. SIH/PDPH - height

    Time frame: at time of inclusion

    height in meter (m)

  7. SIH/PDPH - weight

    Time frame: at time of inclusion

    kilogram (kg)

  8. SIH/PDPH - modified Ranking scale

    Time frame: at time of inclusion

    range in 0-6, 0 indicating best health

  9. SIH/PDPH - pre-existing Neurological deficits (yes/no)

    Time frame: at time of inclusion

    Neurological deficits due to previously attempted treatments at the time of inclusion

  10. SIH/PDPH - Neurological deficits in routine clinical testing

    Time frame: at time of inclusion

    descriptive

  11. SIH - Montreal cognitive Assessment

    Time frame: at time of inclusion

    range 0-30, 30 indicating best performance

  12. SIH - Trail-making test part B

    Time frame: at time of inclusion

    in minutes needed to fulfill the task

  13. PDPH -BMI

    Time frame: at time of inclusion

    kg/m^2

  14. SIH/PDPH - Regular use of stimuli > 6 months (yes/no)

    Time frame: at time of inclusion

    Nicotine, Alcohol, Recreational drugs

  15. SIH/PDPH - Headache-Impact-Test (HIT)-6

    Time frame: at time of inclusion

    Headache-Impact-Test (HIT)-6 range 36 to 78 points, 78 indicating highest impact of headaches.

  16. SIH/PDPH - 5 dimensions /5 levels European Quality of life questionaire (EQ-5D-5L) Index

    Time frame: at time of inclusion

    <0 to 1, with 1 indicating unimpaired health

  17. SIH/PDPH - Self-Administered Comorbidity Questionaire (SCQ)

    Time frame: at time of inclusion

    13-item Self-Adminestered Comorbidity Questionaire (SCQ), range 0 to 39, 0 indicating lowest burden

  18. PDPH - Patient'S Global Impression of Change (PIGC)

    Time frame: at time of inclusion

    range 7 - 42, 7 indicating highest improvement

  19. SIH - Opening pressure on lumbar puncture if performed (not recommended in routine), or myelogram

    Time frame: up to 4 weeks

    cmH2O

  20. SIH/PDPH - Total Bern-Score MRI head according to Dobrocky et al.

    Time frame: up to 4 weeks

    range 0 to 9 with 9 indicating highest likelihood of a spinal CSF leak

  21. SIH/PDPH - Subitems Bern-Score MRI head according to Dobrocky et al.

    Time frame: up to 4 weeks

    Meningeal enhancement (yes/no), Subdural fluid (yes/no), Venous Distention (yes/no), Effaced suprasellar distance (yes/no), Effaced mamillopontine distance (yes/no), Effaced prepontine distance (yes/no)

  22. SIH - MRI head - Superficial Siderosis

    Time frame: up to 4 weeks

    (yes/no)

  23. SIH - MRI head - Layered calvarial hyperostosis

    Time frame: up to 4 weeks

    (yes/no)

  24. SIH - Sinus vein thrombosis

    Time frame: up to 4 weeks

    (yes/no)

  25. SIH/PDPH - Volumetry of the CSF-space MRI head & spine

    Time frame: up to 4 weeks

    mm^3

  26. SIH/PDPH - Volumetry of the CNS MRI head & spine

    Time frame: up to 4 weeks

    mm^3

  27. SIH/PDPH - Imaging Density score

    Time frame: up to 4 weeks

    Density scores of the intracranial compartments MRI head & spine

  28. SIH/PDPH - Total radiation dose applied per diagnostic procedure with radiation performed

    Time frame: at primary workup

    Sievert

  29. SIH - Myelography number

    Time frame: up to 24 weeks

    Number of myelographies performed for precise localization

  30. SIH - Type of myelography technique applied (yes/no)

    Time frame: up to 4 weeks

    conventional,digital subtraction, dynamic CT, Cone-beam CT, Photon-counting CT, fluoroscopy, Other (specify)

  31. SIH - Adverse events during myelography (yes/no)

    Time frame: up to 4 weeks

    nausea, dizziness/vertigo, emesis, allergic reaction, seizure, treatment intensive care unit (independent of cause))

  32. SIH - Headache before and after myelogram

    Time frame: up to 4 weeks

    in 0-10, 10 numeric rating scale

  33. SIH - Positioning during index myelography that proofs the leak (yes/no)

    Time frame: up to 4 weeks

    prone, lateral decubitus, supine

  34. SIH - myelography that proofs the leak performed applying (yes/no)

    Time frame: up to 4 weeks

    resisted insipration, pressuization, valsalva maneuver

  35. SIH/PDPH - Lumbar Infusiontest - Pressure at baseline

    Time frame: up to 4 weeks

    pressure (mmHg)

  36. SIH/PDPH - Lumbar Infusiontest - Resistence to CSF outflow (Rcsf)

    Time frame: up to 4 Weeks

    mmHg/(ml/min)

  37. SIH/PDPH - Lumbar Infusiontest - Elastance

    Time frame: up to 4 weeks

    Elastance coefficient (1/ml)

  38. SIH/PDPH - Lumbar Infusiontest - Pressure-Volume-Index

    Time frame: up to 4 weeks

    ml

  39. SIH/PDPH - Lumbar Infusiontest - Needle resistance

    Time frame: up to 4 weeks

  40. SIH/PDPH - PET-CT - Evidence of CSF-loss (yes/no)

    Time frame: up to 4 weeks

  41. SIH/PDPH - PET-CT if performed -

    Time frame: up tp 4 weeks

    half-life of the tracer in the CSF space (minutes)

  42. SIH/PDPH - Laboratory parameters at diagnosis (normal/abnormal)

    Time frame: up to 4 weeks after inclusion

    • complete routine Blood analysis (including: cellcount, electrolytes, coagulation, renal function, thyroid marker) (normal/abnormal)
    • complete routine CSF-analysis (including: cell count, protein) (normal/abnormal)
  43. SIH - CSF leak types identified by dynamic myelography (yes/no)

    Time frame: up to 4 weeks

    • Ventral dural leak
    • Lateral dural leak
    • CSF-venous fistula, single
    • CSF-venous fistula, multiple
    • Sacral dural leak
    • CSF-lymphatic fistula
    • Dorsal dural leak
    • Undefined
  44. SIH - Multiples leaks (yes/no)

    Time frame: up to 4 weeks

  45. SIH - Level of spinal CSF leak (spinal segment) and side in myelogram

    Time frame: up to 4 weeks

  46. SIH - In case of surgery: spinal segment and side confirmed? (yes/no)

    Time frame: up to 4 weeks

  47. SIH/PDPH - Experience of leading interventionalist in SIH-diagnostics/year

    Time frame: up to 4 weeks

  48. SIH/PDPH - Disease duration at time of therapy

    Time frame: up to 4 weeks

    month

  49. SIH/PDPH - Therapy performed after CSF leak diagnosis (yes/no)

    Time frame: up to 4 weeks

    Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery with patching, Minimally invasive surgery with clipping, Minimally invasive surgery with disconnection, Open surgery, dorsal approach, Open surgery, ventral approach, Open surgery, transforaminal approach, Surgery, other techniques, Medical PDPH treatment, Other symptomatic treatment, e.g. infiltration N. occipitalis, Untargeted lumbar platelet-rich fibrin patch

  50. SIH/PDPH - Experience of leading surgeon in SIH/PDPH-surgeries/year

    Time frame: up to 4 weeks or longer, depending on the number of surgeries

    in numbers of SIH/PDPH-surgeries/year

  51. SIH/PDPH - Interventions needed addressing secondary complications of spinal CSF leaks, especially chronic subdural hematoma

    Time frame: up to 4 weeks

    Twist drill craniostomy (yes/no), Burr hole craniostomy (yes/no ), Mini craniotomy (yes/no), Conventional trepanation (yes/no), Use of drains and any form of controlled lavage (saline and or clot lysis) (yes/no,), Embolization of MMA (middle meningeal arteria) (yes/no), Other intervention (yes/no)

  52. PDPH - Event of putative dural puncture

    Time frame: up to 4 weeks

    date

  53. PDPH - Event of putative dural puncture (yes/ no)

    Time frame: up to 4 weeks

    • Diagnostic lumbar puncture
    • Diagnostic lumbar puncture with drainage in idiopathic intracranial hypertension
    • Diagnostic lumbar puncture with drainage in idiopathic normal-pressure hydrocephalus
    • Peridural anesthesia in obstetrics
    • Spinal anesthesia in obstetrics
    • Peridural anesthesia, other intervention
    • Spinal anesthesia, other intervention
    • Infiltration
    • others
  54. SIH/PDPH - adverse events related to current treatment at discharge (yes/no)

    Time frame: up to 4 weeks

    Rebound hypertension, Persistence/Reoccurrence of the leak, Suture insufficiency, Infect (systemic/local), Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others

  55. PDPH - Lumbar segment of putative dural puncture known (yes/no)

    Time frame: up to 4 weeks

  56. PDPH - Puncture under imaging guidance

    Time frame: up to 4 weeks

    "location truly known"

  57. PDPH - Duration between (putative) dural puncture until the onset of symptoms

    Time frame: up to 4 weeks

    days

  58. PDPH - Time to first blood patch

    Time frame: up to 4 weeks

    days

  59. PDPH - Number of bloodpatches received before admission

    Time frame: up to 4 weeks

  60. PDPH - Prior treatments at the time of admission (yes/no)

    Time frame: up to 4 weeks

    Fluids, Caffeine, Bedrest, Medical treatment, Other treatment, e.g., infiltrations, Untargeted lumbar bloodpatch, Surgery

  61. PDPH - Post-dural puncture pseudomeningocele ("arachnoid bleb")

    Time frame: up to 4 weeks

    (yes/no)

  62. PDPH - Spinal Segment location of the "arachnoid bleb"

    Time frame: up to 4 weeks

  63. PDPH - Identified CSF leak types by dynamics myelography and/or intraoperatively:

    Time frame: up to 4 weeks

    ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak None

  64. PDPH - Intraoperatively Identified membranes (yes/no)

    Time frame: up to 4 weeks

    neo-membranes (pseudo dura), webs, funnels

  65. PDPH - Dinosaur-tail sign (yes/no)

    Time frame: at time of inclusion

  66. PDPH - specific segment of identified intraoperative membranes (descriptive)

    Time frame: up to 4 weeks

  67. PDPH - CSF leak types identified by dynamic myelography and/or intraoperatively

    Time frame: up to 4 weeks

    ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak, None

  68. PDPH - Diagnostic procedures performed (yes/no, number)

    Time frame: uo to 4 weeks

    CT Head, MRI head, MRI spine, Dynamic digital subtraction myelogram, Dynamic CT-myelogram, Photon-counting CT-myelogram, Cone-beam myelogram, Infusion testing, PET-CT, Other (to exclude/confirm alternative diagnosis)

  69. PDPH - Volume lumbar bloodpatch

    Time frame: up to 4 weeks

    ml

  70. SIH/PDPH - work capacity

    Time frame: at time of inclusion

    range 0 to 5, 0 indicating full capacity

  71. SIH/PDPH -complaints

    Time frame: at time of inclusion

    • current complaints (descriptively)
    • most stressful complaint (descriptively)
  72. SIH/PDPH - headache severity

    Time frame: at time of inclusion

    range 0 to 10, 10 indicating most severe pain

  73. SIH/PDPH - Days within the last month

    Time frame: at time of inclusion

    • with headaches
    • with pain medication intake in the last month
  74. SIH/PDPH - maximum duration being continuously upright

    Time frame: at time of inclusion

    hours

  75. SIH/PDPH - severeness of dizziness

    Time frame: at time of inclusion

    • in 0 to 10, 10 being most severe
  76. SIH/PDPH - Severeness of shoulder- and neck pain

    Time frame: at time of inclusion

    • in 0 to 10, 10 being most severe
  77. SIH/PDPH - severeness of nausea

    Time frame: at time of inclusion

    • in 0 to 10, 10 being most severe
  78. SIH/PDPH - severeness of hearing disturbances and tinnitus

    Time frame: at time of inclusion

    • in 0 to 10, 10 being most severe
  79. SIH/PDPH - severeness of cognitive deficits

    Time frame: at time of inclusion

    • in 0 to 10, 10 being most severe
  80. SIH/PDPH - severeness of visual disturbances

    Time frame: at time of inclusion

    • in 0 to 10, 10 being most severe
  81. SIH/PDPH - . ability to focus and concentrate

    Time frame: at time of inclusion

    rated between 0 to 5, with 5 indicating highest burden

  82. SIH/PDPH - MRI spine: Spinal longitudinal extradural fluid collection (SLEC) (yes/no)

    Time frame: up to 4 weeks

  83. SIH/PDPH - MRI-spine: DiverTICula (TIC) ≥8mm (yes/no)

    Time frame: up to 4 weeks

    number of TICs ≥8mm

  84. SIH/PDPH - Volumetry of epidural spinal veins at C2

    Time frame: up to 4 weeks

    mm^3

  85. SIH/PDPH - MRI spine: Enlarged cervical epidural spinal veins at C2

    Time frame: up to 4 weeks

    yes/no

  86. SIH/PDPH - lumbar infusion test - pressure at tilt down

    Time frame: up to 4 weeks after inclusion

    mmHg

  87. SIH/PDPH - lumbar infusion test - pressure at tilt up 10°

    Time frame: up to 4 weeks after inclusion

    mmHg

  88. SIH/PDPH - lumbar infusion test - pressure at tilt up 30°

    Time frame: up to 4 weeks after inclusion

    mmHg

  89. SIH/PDPH - lumbar infusion test - pressure at plateau

    Time frame: up to 4 weeks after inclusion

    mmHg

  90. SIH/PDPH - Laboratory parameters at diagnosis (decriptive)

    Time frame: up to 4 weeks after inclusion

    • Routine Blood analysis
    • Abnormal CSF-analysis
  91. SIH/PDPH - Lumbar Infusiontest - amplitude at baseline

    Time frame: up to 4 weeks

    mmHg

  92. SIH/PDPH - lumbar infusion test - amplitude at tilt down

    Time frame: up to 4 weeks after inclusion

    mmHg

  93. SIH/PDPH - lumbar infusion test -amplitude at tilt up 10°

    Time frame: up to 4 weeks after inclusion

    mmHg

  94. SIH/PDPH - lumbar infusion test - amplitude at tilt up 30°

    Time frame: up to 4 weeks after inclusion

    mmHg

  95. SIH/PDPH - lumbar infusion test - amplitude at plateau

    Time frame: up to 4 weeks after inclusion

    mmHg

  96. SIH/PDPH - PET-CT if performed -

    Time frame: up tp 4 weeks

    half-life of the tracer o0ver the convexities (minutes)

  97. SIH/PDPH - Results of neuropathological tissue analysis if assessed (descriptive)

    Time frame: up to 6 weeks

    epidural membranes (descriptive) arachnoid funnels (descriptive) diverticula (descriptive) epidural vessels (descriptive)

  98. SIH/PDPH - phase-contrast MRI : CSF-velocity

    Time frame: up to 4 weeks

    cm/s

  99. SIH/PDPH - phase-contrast MRI: Stroke-volume CSF

    Time frame: up to 4 weeks

    ml

  100. SIH/PDPH - phase-contrast MRI: Spinal cord motion

    Time frame: up to 4 weeks

    mm

  101. SIH/PDPH - phase-contrast MRI: Spinal cord velocities

    Time frame: up to 4 weeks

    cm/s

  102. SIH/PDPH - MRI spine: Bud-on-branching sign (yes/no)

    Time frame: up to 4 weeks

  103. SIH/PDPH - MRI spine: Localized flow-voids in sagittal spine T2 images (yes/no)

    Time frame: up to 4 weeks

Other outcomes

  1. SIH/PDPH - Follow up-Reported adverse events related to treatment (yes/no)

    Time frame: 4 weeks and 3 month after treatment

    Rebound hypertension, Reoccurrence of the leak, Suture insufficiency, Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others

  2. SIH/PDPH - Follow up-Duration of treatment for rebound hypertension after therapy of the CSF leak

    Time frame: 4 weeks after treatment

    days

  3. SIH/PDPH - Follow up-Average dosage of acetazolamide per day

    Time frame: 4 weeks after treatment

    mean mg/d

  4. SIH/PDPH - Follow up - Total Bern-Score, according to Dobrocky et al.

    Time frame: 3 months after treatment

    range 0 to 9, 9 indicating highest likelihood of spinal CSF leak

  5. SIH/PDPH - Follow up - Subitems Bern-Score, according to Dobrocky et al.

    Time frame: 3 months after treatment

    • Meningeal enhancement (yes/no)
    • Subdural fluid (yes/no)
    • Venous distention (yes/no)
    • Effaced suprasellar distance (yes/no)
    • Effaced mamillopontine distance (yes/no)
    • Effaced prepontine distance (yes/no)
  6. SIH/PDPH - Follow up - Spinal longitudinal extradural fluid collection at site of the leak (SLEC) (only if present before)

    Time frame: 3 months after treatment

    yes /no

  7. SIH/PDPH - Follow up - Headache-Impact-Test (HIT)-6

    Time frame: 3, 6, 12 & 24 months after treatment

    range 36 to 78 points, 78 indicating highest impact of headaches

  8. SIH/PDPH - Follow up - 5 dimension/ 5 levels European Quality of life questionnaire (EQ-5D-5L)

    Time frame: 3, 6, 12, & 24 months after treatment

    <0 to1, 1indicating unimpaired health

  9. SIH/PDPH - Follow up - Patient's Global Impression of Change (PGIC)

    Time frame: 3, 6, 12 & 24 months after treatment

    range 7 to 42, 7 indicating highest improvement

  10. SIH/ PDPH - Follow up - Self-administered comorbidity questionnaire (SCQ)

    Time frame: 12 & 24 months after treatment

    range 0 to 39, 0 indicating lowest burden

  11. SIH/PDPH - follow-up - current working capacity

    Time frame: at 4 weeks & 3, 6, 12 & 24 months

    range 0 to 5, 0 indicating full capacity

  12. SIH/PDPH - follow-up - complaints

    Time frame: 4 week, 3, 6, 12 & 24 months

    • current complaints (descriptively)
    • most stressful complaint (descriptively)
  13. SIH/PDPH - follow-up - headache severity

    Time frame: 4 week, 3, 6, 12 & 24 months

    range 0 to 10, 10 indicating most severe pain

  14. SIH/PDPH - follow-up - Days within the last month

    Time frame: 4 weeks, 3, 6, 12, 24 months

    with headaches with pain medication intake in the last month

  15. SIH/PDPH - follow-up - maximum duration being continuously upright

    Time frame: 4 weeks, 3, 6, 12 & 24 months

    hours

  16. SIH/PDPH - follow-up - severeness of dizziness

    Time frame: 4 weeks, 3, 6, 12 &24 months

    • in 0 to 10, 10 being most severe
  17. SIH/PDPH - follow-up - Severeness of shoulder- and neck pain

    Time frame: 4 weeks, 3, 6, 12 & 24 months

    in 0 to 10, 10 being most severe

  18. SIH/PDPH - follow-up - severeness of nausea

    Time frame: 4 weeks, 3, 6, 12 & 24 months

    in 0 to 10, 10 being most severe

  19. SIH/PDPH - follow-up - severeness of hearing disturbances and tinnitus

    Time frame: 4 weeks, 3, 6, 12 & 24 months

    in 0 to 10, 10 being most severe

  20. SIH/PDPH - follow-up - severeness of cognitive deficits

    Time frame: 4 weeks, 3, 6, 12 & 24 months

    in 0 to 10, 10 being most severe

  21. SIH/PDPH - follow-up - severeness of visual disturbances

    Time frame: 4 weeks, 3, 6, 12 & 24 months

    in 0 to 10, 10 being most severe

  22. SIH/PDPH - follow-up - exhaustion

    Time frame: 4 weeks, 3, 6,12 &24 months

    rated between 0 to 5, with 5 indicating highest burden

  23. SIH/PDPH - follow-up - ability to focus and concentrate

    Time frame: 4 weeks, 3, 6, 12 & 24 months

    rated between 0 to 5, with 5 indicating highest burden

  24. SIH/PDPH - follow-up - phase-contrast MRI: CSF-velocity (if performed)

    Time frame: up to 6 months after treatment

    cm/s

  25. SIH/PDPH - follow-up - phase-contrast MRI Stroke-volume CSF (if performed)

    Time frame: up to 6 months after treatment

    ml

  26. SIH/PDPH - follow-up - phase-contrast MRI Spinal cord motion (if performed)

    Time frame: up to 6 months after treatment

    mm

  27. SIH/PDPH - follow-up - phase-contrast MRI Spinal cord velocity (if performed)

    Time frame: up to 6 months after treatment

    cm/s

Study contacts

Contact information is provided by the study sponsor or research team.

Florian Volz, Dr. med.

CONTACT

[email protected]

Katharina Wolf, Dr. med.

CONTACT

[email protected]

+49 761 270-50010

Sponsors and collaborators

Lead sponsor

University Hospital Freiburg

Other

Registry information

Acronym: SEAL

Important dates

Study start
2024
Primary completion
2034
Study completion
2036
First posted
Dec 2, 2024
Registry last updated
Dec 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.